198 related articles for article (PubMed ID: 31714026)
21. Cell growth inhibition by 3-deoxysappanchalcone is mediated by directly targeting the TOPK signaling pathway in colon cancer.
Zhao R; Huang H; Choi BY; Liu X; Zhang M; Zhou S; Song M; Yin F; Chen H; Shim JH; Bode AM; Dong Z; Lee MH
Phytomedicine; 2019 Aug; 61():152813. PubMed ID: 31035049
[TBL] [Abstract][Full Text] [Related]
22. TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation.
Uchida E; Suwa S; Yoshimoto R; Watanabe K; Kasama T; Miura O; Fukuda T
Int J Oncol; 2019 May; 54(5):1785-1796. PubMed ID: 30864683
[TBL] [Abstract][Full Text] [Related]
23. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
Malek E; Driscoll JJ
Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
[TBL] [Abstract][Full Text] [Related]
24. PBK/TOPK mediates promyelocyte proliferation via Nrf2-regulated cell cycle progression and apoptosis.
Liu Y; Liu H; Cao H; Song B; Zhang W; Zhang W
Oncol Rep; 2015 Dec; 34(6):3288-96. PubMed ID: 26503118
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and biological evaluation of novel 1-phenyl phenanthridin-6(5H)-one derivatives as anti-tumor agents targeting TOPK.
Hu QF; Gao TT; Shi YJ; Lei Q; Liu ZH; Feng Q; Chen ZJ; Yu LT
Eur J Med Chem; 2019 Jan; 162():407-422. PubMed ID: 30453248
[TBL] [Abstract][Full Text] [Related]
26. PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21.
Hu F; Gartenhaus RB; Eichberg D; Liu Z; Fang HB; Rapoport AP
Oncogene; 2010 Oct; 29(40):5464-74. PubMed ID: 20622899
[TBL] [Abstract][Full Text] [Related]
27. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth.
Kim DJ; Li Y; Reddy K; Lee MH; Kim MO; Cho YY; Lee SY; Kim JE; Bode AM; Dong Z
Cancer Res; 2012 Jun; 72(12):3060-8. PubMed ID: 22523035
[TBL] [Abstract][Full Text] [Related]
28. Topical application of TOPK inhibitor OTS514 suppresses psoriatic progression by inducing keratinocytes cell cycle arrest and apoptosis.
Zeng F; Lu H; Wu M; Dai C; Li J; Wang J; Hu G
Exp Dermatol; 2023 Oct; 32(10):1823-1833. PubMed ID: 37578092
[TBL] [Abstract][Full Text] [Related]
29. TOPKi-NBD: a fluorescent small molecule for tumor imaging.
Pirovano G; Roberts S; Reiner T
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):1003-1010. PubMed ID: 31734783
[TBL] [Abstract][Full Text] [Related]
30. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
Santo L; Hideshima T; Cirstea D; Bandi M; Nelson EA; Gorgun G; Rodig S; Vallet S; Pozzi S; Patel K; Unitt C; Squires M; Hu Y; Chauhan D; Mahindra A; Munshi NC; Anderson KC; Raje N
Clin Cancer Res; 2011 May; 17(10):3259-71. PubMed ID: 21430070
[TBL] [Abstract][Full Text] [Related]
31. Novel Interleukin-6 Inducible Gene PDZ-Binding Kinase Promotes Tumor Growth of Multiple Myeloma Cells.
Ota A; Hanamura I; Karnan S; Inaguma S; Takei N; Lam VQ; Mizuno S; Kanasugi J; Wahiduzzaman M; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Ikeda H; Takami A; Hosokawa Y
J Interferon Cytokine Res; 2020 Aug; 40(8):389-405. PubMed ID: 32721246
[TBL] [Abstract][Full Text] [Related]
32. The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo.
Sanchez E; Li M; Patil S; Soof CM; Nosrati JD; Schlossberg RE; Vidisheva A; Tanenbaum EJ; Hekmati T; Zahab B; Wang C; Tang G; Chen H; Berenson JR
Ann Hematol; 2019 Mar; 98(3):691-703. PubMed ID: 30635766
[TBL] [Abstract][Full Text] [Related]
33. PBK expression predicts favorable survival in colorectal cancer patients.
Nagano-Matsuo A; Inoue S; Koshino A; Ota A; Nakao K; Komura M; Kato H; Naiki-Ito A; Watanabe K; Nagayasu Y; Hosokawa Y; Takiguchi S; Kasugai K; Kasai K; Inaguma S; Takahashi S
Virchows Arch; 2021 Aug; 479(2):277-284. PubMed ID: 33638656
[TBL] [Abstract][Full Text] [Related]
34. p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma.
Medicherla S; Reddy M; Ying J; Navas TA; Li L; Nguyen AN; Kerr I; Hanjarappa N; Protter AA; Higgins LS
Anticancer Res; 2008; 28(6A):3827-33. PubMed ID: 19189670
[TBL] [Abstract][Full Text] [Related]
35. Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway.
Xiao W; Xu Z; Chang S; Li B; Yu D; Wu H; Xie Y; Wang Y; Xie B; Sun X; Kong Y; Lan X; Bu W; Chen G; Gao L; Wu X; Shi J; Zhu W
Cancer Lett; 2019 Mar; 444():45-59. PubMed ID: 30583070
[TBL] [Abstract][Full Text] [Related]
36. Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
Zheng J; Sha Y; Roof L; Foreman O; Lazarchick J; Venkta JK; Kozlowski C; Gasparetto C; Chao N; Ebens A; Hu J; Kang Y
Cancer Lett; 2019 Jan; 440-441():1-10. PubMed ID: 30312729
[TBL] [Abstract][Full Text] [Related]
37. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
Zhu K; Cheng X; Wang S; Zhang H; Zhang Y; Wang X; Chen Y; Wu J
Front Endocrinol (Lausanne); 2021; 12():706909. PubMed ID: 35126305
[TBL] [Abstract][Full Text] [Related]
38. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
[TBL] [Abstract][Full Text] [Related]
39. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A
Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440
[TBL] [Abstract][Full Text] [Related]
40. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.
Cholujova D; Bujnakova Z; Dutkova E; Hideshima T; Groen RW; Mitsiades CS; Richardson PG; Dorfman DM; Balaz P; Anderson KC; Jakubikova J
Br J Haematol; 2017 Dec; 179(5):756-771. PubMed ID: 29048129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
